Both in Pharmaceuticals
Protagonist Therapeutics vs Spyre Therapeutics
Over the past year PTGX returned +87.4% and SYRE returned +331.0%; their daily moves had a correlation of 0.37.
PTGX +87.4% SYRE +331.0%Growth of $1, one year, split-adjusted
| Metric | PTGX | SYRE |
|---|---|---|
| Price | $143.37 | $99.04 |
| Market cap | $9.28B | $9.26B |
| Today | +2.23% | −0.23% |
| 1 month | +3.4% | +23.6% |
| 6 months | +37.9% | +35.7% |
| Year to date | +64.2% | +202.3% |
| 1 year | +88.8% | +316.5% |
| Revenue growth (YoY) | +3749.2% | — |
| Gross margin | 100.0% | — |
| Net margin | 76.3% | — |
| P/E (TTM) | 111.9× | — |
| Price / sales | 32.9× | — |
| Net cash | $782.6M | $1.07B |
| Dividend yield | — | — |
| Volatility (60d) | 32.0% | 59.0% |
| Short % of float | 16.8% | 15.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).